Anika Therapeutics ANIK Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
- Anika Therapeutics (ANIK) reported cash provided by (used in) financing activity, including discontinued operation of -$701K in Q2 2026.
- What is the long-term trend for Anika Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
- Over 3 years (2021 to 2025), Anika Therapeutics's cash provided by (used in) financing activity, including discontinued operation has grown at a 16.2% compound annual growth rate (CAGR), from -$6.84M to -$10.73M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.